Pharmaceutical Preparations · E9 · CIK 1821586
Advancing novel therapies for inflammatory skin and joint diseases by developing a tri-specific IL-17 inhibitor
Comparable business profile · signals at a glance
In the 90 days to Dec 9, 2025: 1 insider bought $99K · 3 sold $52.9M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 9, 2025 | Reich KristianChief Scientific Officer | Sell | 72,908 | $14.43 | $1.1M |
| Dec 9, 2025 | Santos Da Silva JorgeChief Executive Officer | Sell | 70,000 | $14.49 | $1.0M |
| Dec 8, 2025 | Santos Da Silva JorgeChief Executive Officer | Sell | 130,000 | $15.08 | $2.0M |
| Dec 8, 2025 | Reich KristianChief Scientific Officer | Sell | 130,000 | $15.08 | $2.0M |
| Oct 8, 2025 | Bodenstedt MatthiasChief Financial Officer | Buy | 10,870 | $9.09 | $99K |
| Sep 30, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 5,827 | $6.96 | $41K |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 3,390,943 | $7.58 | $25.7M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 2,800,000 | $6.61 | $18.5M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 232,460 | $8.40 | $2.0M |
| Sep 29, 2025 | Cormorant Global Healthcare Master Fund, LpOther | Sell | 70,748 | $9.38 | $664K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.